Skip to main content

Innovating for tomorrow.
Transforming lives today.

Allergan is now part of AbbVie. Together, we are dedicating more to R&D to drive tomorrow’s breakthroughs, while helping people to live better lives today.

With the Allergan acquisition, we are bringing together more than 30 brands and leadership positions to expand and diversify our product portfolio.  This allows us to have immediate scale and profitability to advance our innovative science pipeline that brings patients groundbreaking medicines across a wide spectrum of therapeutic need/critical therapeutic areas.

We continue to build a sustainable company for the long term that provides profitable growth for shareholders, as well as financial flexibility to invest and expand in order to help address the needs of people and communities around the world. 

The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us. I am proud of both organisations and look forward to the opportunities ahead.

Richard A. Gonzalez, chairman and chief executive officer, AbbVie

Two AbbVie doctors wearing goggles and holding vials
Advancing our mission

Learn how the acquisition of Allergan allows us to better serve patients today and invest in the medicines of the future.

Resources

AbbVie is currently reviewing all content on Allergan.com.  As we work through the successful integration of Allergan and consolidation of content, information will be updated.